Abiopharma

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial ofAXPAXLI™ in NPDR

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

New Form 8-K - Passage BIO, Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011143 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - VERU INC. Filed: 2025-08-12 AccNo: 0001193125-25-178463 Size: 258 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - GLAUKOS Corp Filed: 2025-08-12 AccNo: 0001558370-25-011142 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Bruker - Bruker Announces Quarterly Dividend

New Form 10-Q - Milestone Pharmaceuticals Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011141 Size: 7 MB

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Xtant Medical Reports Second Quarter 2025 Financial Results